Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY) (clinicaltrials.gov) - May 15, 2025 - P3 | N=200 | Not yet recruiting | Sponsor: Brainstorm-Cell Therapeutics
New P3 trial • Amyotrophic Lateral Sclerosis • CNS Disorders
|